Skip to content
October 8, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Global Breast Cancer Awareness
  • Navigating the Post-Treatment Journey: Breast Cancer Canada’s October Education Series
  • Global Breast Cancer Awareness

Navigating the Post-Treatment Journey: Breast Cancer Canada’s October Education Series

Nana Muazin October 8, 2026 7 minutes read
navigating-the-post-treatment-journey-breast-cancer-canadas-october-education-series-4

As the landscape of oncology continues to evolve, the transition from active cancer treatment to long-term survivorship remains a critical, albeit complex, phase for patients. Recognizing the urgent need for evidence-based guidance, Breast Cancer Canada (BCC) has launched its October Education Series, a comprehensive virtual program designed to empower patients, survivors, and their families.

By addressing the multifaceted nature of breast cancer—ranging from clinical recurrence risks to the emotional and physical nuances of life after therapy—this series serves as a vital resource for those navigating the "new normal" following a diagnosis.


Main Facts: The Pillars of Survivorship

The October 2026 series focuses on four distinct but interconnected domains of patient care. The program opened on October 1 with a deep dive into medical risk assessment, led by Dr. Nathalie Levasseur of BC Cancer. The subsequent sessions are designed to build upon this clinical foundation by addressing nutrition, physical rehabilitation, and emotional integration.

Clinical Risk Assessment (October 1)

The series began by addressing the most pressing anxiety for many patients: the fear of recurrence. Dr. Levasseur’s session focused on HR+/HER2- early breast cancer, emphasizing that recurrence risk is not a static number, but a dynamic profile shaped by clinical factors, pathology, and genomic testing.

Nutritional Strategy (October 8)

Recognizing the overwhelming volume of conflicting dietary advice online, Registered Dietitian and cancer survivor Jean LaMantia is scheduled to provide a roadmap for post-treatment nutrition. The focus is on evidence-based strategies for maintaining muscle mass, bone health during endocrine therapy, and sustainable weight management.

Physical Well-being (October 15)

Physical changes often persist long after the final round of chemotherapy or radiation. Voula Pantelis, an advocate and expert in post-mastectomy care, will address the tangible realities of survivorship, including scar management, lymphedema, and the gradual return to physical activity.

Emotional Integration (October 22)

The final session addresses the psychological transition. Founder of Rising Lotus and cancer survivor Jacqueline Beatty will introduce the "Root to Rise" framework, designed to help survivors navigate identity shifts, emotional regulation, and the return to professional and personal routines.


Chronology of the October Education Series

The series follows a structured, weekly progression designed to mirror the patient’s journey from clinical management to holistic recovery.

  • October 1, 2026: Risk of Recurrence. Dr. Nathalie Levasseur explored the synthesis of clinical data and genomic insights to help patients understand their personal risk profile.
  • October 8, 2026: Nutrition After Breast Cancer. Jean LaMantia will demystify the complex relationship between diet, cancer risk, and long-term health, moving away from restrictive diets toward balanced, evidence-based nutrition.
  • October 15, 2026: Living Well. Voula Pantelis will discuss the physical reality of the post-treatment body, focusing on comfort, mobility, and body image.
  • October 22, 2026: Moving Emotions Forward. Jacqueline Beatty will conclude the series by providing tools for emotional resilience, setting boundaries, and re-establishing life goals.

Supporting Data: Understanding Recurrence in HR+/HER2- Cancer

For the estimated thousands of Canadians diagnosed with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer, the risk of recurrence is a primary concern.

During her October 1 presentation, Dr. Levasseur highlighted that the shift in cancer care has moved toward individualized risk stratification. Key data points discussed included:

  1. Genomic Testing: The integration of genomic assays allows clinicians to analyze the specific biology of a tumor, moving beyond traditional metrics like tumor size or lymph node involvement.
  2. The Role of CDK4/6 Inhibitors: These therapies have fundamentally changed the prognosis for many patients, significantly reducing the risk of recurrence in high-risk settings.
  3. Endocrine Therapy Compliance: The session reinforced that adherence to long-term hormonal treatments—which can last five to ten years—is the cornerstone of preventing late-stage recurrences.

Dr. Levasseur underscored that while statistical models provide a baseline, they are "tools, not prophecies." She encouraged patients to utilize these metrics to initiate informed conversations with their oncology teams rather than relying on generalized data.


Official Perspectives: Empowering the Patient Voice

The inclusion of both medical professionals and patient advocates in this series is a deliberate strategy by Breast Cancer Canada to bridge the gap between clinical excellence and lived experience.

The Clinical Perspective

Dr. Levasseur’s approach centers on "Patient-Centered Empowerment." By explaining the "why" behind treatment decisions, she argues that patients are better equipped to manage the uncertainty that often lingers after active treatment ends. Her session highlighted the importance of asking specific, pointed questions during follow-up appointments, such as: "What are the key clinical indicators of my specific risk level?" and "How can we optimize my endocrine therapy to balance efficacy with side-effect management?"

The Survivor Perspective

Advocates like Jean LaMantia and Jacqueline Beatty bring a different, equally vital perspective. Their involvement acknowledges that medical success is only one part of the equation. For a survivor, "success" also means being able to navigate a grocery store without fear of "cancer-causing" foods, or returning to a workplace with newfound emotional boundaries. By sharing personal anecdotes alongside professional expertise, they normalize the feelings of isolation that often follow the conclusion of active hospital-based care.


Implications: Building a Sustainable Future for Survivorship

The implications of this series are significant for the Canadian healthcare system. As more breast cancer patients achieve long-term remission, the demand for "survivorship care" increases.

Bridging the Gap in Post-Treatment Support

Traditionally, the healthcare system is highly effective at treating active disease but often leaves a "support vacuum" once the patient is discharged from the oncology unit. The BCC series aims to fill this gap by providing:

  • Actionable Strategies: Moving from abstract medical advice to concrete habits like protein intake for muscle maintenance.
  • Psychological Resilience: Providing frameworks like "Root to Rise" to combat the common experience of "post-treatment anxiety," where the sudden withdrawal of frequent medical monitoring can leave patients feeling abandoned.
  • Standardization of Care: By making these webinars accessible across the country, Breast Cancer Canada is helping to standardize the information available to patients, regardless of whether they are treated in large urban centers or remote communities.

The Role of Advocacy in Modern Oncology

The series highlights that advocacy is not just about fundraising; it is about education and resource allocation. By providing these webinars for free, Breast Cancer Canada ensures that financial status does not prevent a patient from accessing high-quality, expert-led information.

Conclusion

As we look toward the remainder of October 2026, the Breast Cancer Canada series stands as a testament to the resilience of the patient community and the necessity of holistic care. Whether dealing with the clinical complexities of genomic testing or the daily struggle of physical discomfort and emotional adjustment, patients are finding that they are not alone.

For those who missed the opening session with Dr. Levasseur, the recording and accompanying slide decks remain available, serving as a comprehensive archive for anyone seeking to understand their risk and regain control over their health journey. With upcoming sessions on nutrition, physical well-being, and emotional growth, the series offers a holistic roadmap for what it truly means to "live well" beyond a cancer diagnosis.

Patients and caregivers are encouraged to register for the remaining sessions, as each webinar provides not only the latest in expert guidance but also a community of peers navigating similar paths. In the face of uncertainty, knowledge remains the most powerful tool for healing.

About the Author

Nana Muazin

Author

View All Posts

Post navigation

Previous: Unmasking the Tumor’s Neural Network: Oklahoma Research Reveals How Aggressive Breast Cancer Hijacks the Immune System

Related Stories

a-global-partnership-at-a-crossroads-analyzing-the-strained-relationship-between-the-u-s-and-the-who
  • Global Breast Cancer Awareness

A Global Partnership at a Crossroads: Analyzing the Strained Relationship Between the U.S. and the WHO

Sagoh October 8, 2026
navigating-the-post-treatment-journey-breast-cancer-canadas-october-education-series-3
  • Global Breast Cancer Awareness

Navigating the Post-Treatment Journey: Breast Cancer Canada’s October Education Series

Iffa Jayyana October 8, 2026
a-rift-in-global-health-examining-the-strained-relationship-between-the-united-states-and-the-who
  • Global Breast Cancer Awareness

A Rift in Global Health: Examining the Strained Relationship Between the United States and the WHO

Reynand Wu October 8, 2026

Recent Posts

  • Navigating the Post-Treatment Journey: Breast Cancer Canada’s October Education Series
  • Unmasking the Tumor’s Neural Network: Oklahoma Research Reveals How Aggressive Breast Cancer Hijacks the Immune System
  • Argenx Halts Sjögren’s Trial for Vyvgart Hytrulo Amid Broader Label Expansion Ambitions
  • Navigating the Intersection of GLP-1 Medications and Breast Cancer: A Growing Area of Research and Patient Concern
  • Bridging the Genomic Divide: How Tameron Harvell is Redefining Precision Oncology from the Bedside to the Lab

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

navigating-the-post-treatment-journey-breast-cancer-canadas-october-education-series-4
  • Global Breast Cancer Awareness

Navigating the Post-Treatment Journey: Breast Cancer Canada’s October Education Series

Nana Muazin October 8, 2026
unmasking-the-tumors-neural-network-oklahoma-research-reveals-how-aggressive-breast-cancer-hijacks-the-immune-system
  • Medical Research and Clinical Trials

Unmasking the Tumor’s Neural Network: Oklahoma Research Reveals How Aggressive Breast Cancer Hijacks the Immune System

Asro October 8, 2026
argenx-halts-sjogrens-trial-for-vyvgart-hytrulo-amid-broader-label-expansion-ambitions
  • Medical Research and Clinical Trials

Argenx Halts Sjögren’s Trial for Vyvgart Hytrulo Amid Broader Label Expansion Ambitions

Nila Kartika Wati October 8, 2026
navigating-the-intersection-of-glp-1-medications-and-breast-cancer-a-growing-area-of-research-and-patient-concern
  • Patient Advocacy and Support

Navigating the Intersection of GLP-1 Medications and Breast Cancer: A Growing Area of Research and Patient Concern

Azzam Bilal Chamdy October 8, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.